Randomized study comparing six times of epirubicin instillation for 2.5 months with six times for two weeks in superficial bladder cancer after transurethral resection of bladder tumor
Not Applicable
- Conditions
- Superficial bladder cancer
- Registration Number
- JPRN-C000000257
- Lead Sponsor
- Japanese Urological Cancer Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
Synchronous CIS G3 tumor Severe complication History of allergy for Epirubicin Active infection Active synchronous malignancy History of upper urinary tract malignancies
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method